Dianthus Therapeutics (NASDAQ:DNTH) Stock: Insider Ryan Savitz Sells 2,561 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 2,561 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $90.14, for a total transaction of $230,848.54. Following the completion of the sale, the executive vice president directly owned 29,276 shares in the company, valued at approximately $2,638,938.64. This represents a 8.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ryan Savitz also recently made the following trade(s):

• On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.03, for a total value of $274,051.32.
• On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.56, for a total value of $1,605,085.44.
• On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.54, for a total value of $9,118,555.02.

Dianthus Therapeutics Stock Up 3.6%

DNTH traded up $3.18 during midday trading on Thursday, hitting $92.48. 921,016 shares of the company were exchanged, compared to its average volume of 931,449. The firm’s 50 day moving average price is $89.05 and its 200-day moving average price is $86.15. Dianthus Therapeutics, Inc. has a 1-year low of $34.29 and a 1-year high of $117.88. The firm has a market capitalization of $5.21 billion, a P/E ratio of -23.18 and a beta of 1.47.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. The company had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $0.46 million. On average, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on DNTH. Roth Capital initiated coverage on Dianthus Therapeutics in a report on Tuesday, October 27th. They issued a “buy” rating and a $113.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and set a $158.00 price objective on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. Truist Financial lifted their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. began coverage on shares of Dianthus Therapeutics in a report on Friday, September 11th. They issued an “overweight” rating and a $135.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $128.77.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Dianthus Therapeutics in the second quarter worth $401,990,000. Wellington Management Group LLP increased its stake in Dianthus Therapeutics by 24.4% in the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after purchasing an additional 634,099 shares in the last quarter. Jennison Associates LLC acquired a new position in shares of Dianthus Therapeutics during the first quarter valued at about $40,713,000. Assenagon Asset Management S.A. raised its holdings in shares of Dianthus Therapeutics by 160.9% during the third quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock valued at $64,474,000 after purchasing an additional 451,597 shares during the period. Finally, Spruce Street Capital LP bought a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $34,587,464. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.